PRS-342: Repeating the Targeted Co-Stim Paradigm

Candidate Targets Indication Partner Our Commercial
Rights
Discovery Preclinical IND-
enabling
Phase I Phase Ib/IIa
PRS-342 4-1BB/GPC3 Bispecific Immuno-Oncology Worldwide
Discovery Phase completed
Pre-Clinical Phase in progress
IND-enabling Phase not started
Phase 1 not started
Phase 2 not started

Pieris sees substantial potential to repeat the paradigm of its lead compound in immuno-oncology by combining different tumor-targeting and immune-activating modalities in a bispecific compound.

PRS-342 is using a CD137-specific Anticalin with a GPC3-targeting antibody. Glypican 3 (GPC3) is an oncofetal antigen with almost no expression in normal adult tissue, therefore favoring a tumor-targeted immunotherapy approach. The target is thought to be involved in modulation of growth in the predominantly mesodermal tissues and organs during development. Its expression is pronounced in multiple cancers that are known to have CD137+tumor-infiltratiting lymphocytes including hepatocellular Carcinoma, Merkel Cell Carcinoma and Melanoma.